EPIC Program Annual Data Tables 2007-2008: Table VIII
| Rank by Number of Claims | Drug and Strength | Drug Type** | Number of Claims | EPIC Payments | Rank by Payment |
|---|---|---|---|---|---|
| Top 20 Totals | 2,229,275 | $95,578,089 | |||
| Percent of Top 20 Drugs to Total Paid Claims | 20.89% | 21.20% | |||
| 1 | PLAVIX (75 MG) | SS | 284,617 | $25,229,867 | 1 |
| 2 | HYDROCHLOROTHIAZIDE (25 MG) | Gen | 204,297 | $265,330 | 345 |
| 3 | FUROSEMIDE (40 MG) | Gen | 139,548 | $253,775 | 360 |
| 4 | LIPITOR (10 MG) | SS | 126,355 | $7,866,583 | 6 |
| 5 | OMEPRAZOLE (20 MG) | Gen | 118,267 | $3,932,517 | 17 |
| 6 | FOSAMAX (70 MG) | BNMS | 114,738 | $6,589,908 | 7 |
| 7 | NEXIUM (40 MG) | SS | 111,836 | $13,838,296 | 2 |
| 8 | AMLODIPINE BESYLATE (5 MG) | Gen | 102,243 | $1,352,073 | 66 |
| 9 | FUROSEMIDE (20 MG) | Gen | 99,656 | $154,485 | 532 |
| 10 | LIPITOR (20 MG) | SS | 97,839 | $8,453,821 | 5 |
| 11 | PROTONIX (40 MG) | BNMS | 93,415 | $8,968,359 | 4 |
| 12 | METOPROLOL TARTRATE (50 MG) | Gen | 92,454 | $190,860 | 447 |
| 13 | METOPROLOL SUCCINATE (50 MG) | Gen | 86,889 | $1,007,274 | 90 |
| 14 | SIMVASTATIN (20 MG) | Gen | 83,481 | $1,750,088 | 49 |
| 15 | AMLODIPINE BESYLATE (10 MG) | Gen | 83,416 | $1,428,838 | 63 |
| 16 | METFORMIN HCL (500 MG) | Gen | 82,816 | $515,855 | 177 |
| 17 | SPIRIVA (18MCG) | SS | 78,469 | $5,152,439 | 11 |
| 18 | ATENOLOL (50 MG) | Gen | 78,456 | $202,770 | 422 |
| 19 | FLOMAX (0.4 MG) | SS | 75,380 | $4,216,119 | 15 |
| 20 | ACTONEL (35 MG) | SS | 75,103 | $4,208,832 | 16 |
* Table VIII lists the top 20 drugs ranked by number of adjudicated claims for the program year (October 1, 2007-September 30, 2008) as well as the percentage of the totals they represent for the year.
** Drug Type values are BNMS='Brand Name Multi-Source', Gen='Generic and SS='Sole Source'.
